vs
Side-by-side financial comparison of Local Bounti Corporation (LOCL) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Local Bounti Corporation is the larger business by last-quarter revenue ($12.5M vs $9.1M, roughly 1.4× Protalix BioTherapeutics, Inc.). Protalix BioTherapeutics, Inc. runs the higher net margin — -60.3% vs -69.8%, a 9.5% gap on every dollar of revenue. On growth, Local Bounti Corporation posted the faster year-over-year revenue change (23.7% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-3.6M). Over the past eight quarters, Local Bounti Corporation's revenue compounded faster (21.9% CAGR vs -6.7%).
Local Bounti Corporation is a U.S.-based sustainable indoor agriculture firm growing fresh, pesticide-free leafy greens, herbs and produce via advanced hydroponic and vertical farming tech. It serves North American retail and food service partners, focusing on low environmental impact and stable year-round supply.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
LOCL vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.5M | $9.1M |
| Net Profit | $-8.7M | $-5.5M |
| Gross Margin | 12.2% | 49.4% |
| Operating Margin | -106.1% | -51.1% |
| Net Margin | -69.8% | -60.3% |
| Revenue YoY | 23.7% | -49.9% |
| Net Profit YoY | 76.0% | -184.8% |
| EPS (diluted) | $1.52 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.5M | $9.1M | ||
| Q3 25 | $12.2M | $17.9M | ||
| Q2 25 | $12.1M | $15.7M | ||
| Q1 25 | $11.6M | $10.1M | ||
| Q4 24 | $10.1M | $18.2M | ||
| Q3 24 | $10.2M | $18.0M | ||
| Q2 24 | $9.4M | $13.5M | ||
| Q1 24 | $8.4M | — |
| Q4 25 | $-8.7M | $-5.5M | ||
| Q3 25 | $-26.4M | $2.4M | ||
| Q2 25 | $-21.6M | $164.0K | ||
| Q1 25 | $-37.7M | $-3.6M | ||
| Q4 24 | $-36.3M | $6.5M | ||
| Q3 24 | $-34.3M | $3.2M | ||
| Q2 24 | $-25.3M | $-2.2M | ||
| Q1 24 | $-24.1M | — |
| Q4 25 | 12.2% | 49.4% | ||
| Q3 25 | 11.5% | 53.4% | ||
| Q2 25 | 12.2% | 62.5% | ||
| Q1 25 | 12.6% | 19.1% | ||
| Q4 24 | 5.4% | 78.7% | ||
| Q3 24 | 13.8% | 53.4% | ||
| Q2 24 | 14.3% | 29.8% | ||
| Q1 24 | 9.4% | — |
| Q4 25 | -106.1% | -51.1% | ||
| Q3 25 | -149.4% | 11.9% | ||
| Q2 25 | -127.7% | 7.5% | ||
| Q1 25 | -135.6% | -41.0% | ||
| Q4 24 | -166.6% | 39.6% | ||
| Q3 24 | -176.0% | 22.2% | ||
| Q2 24 | -146.8% | -18.0% | ||
| Q1 24 | -122.9% | — |
| Q4 25 | -69.8% | -60.3% | ||
| Q3 25 | -216.6% | 13.2% | ||
| Q2 25 | -178.3% | 1.0% | ||
| Q1 25 | -324.6% | -35.8% | ||
| Q4 24 | -360.1% | 35.6% | ||
| Q3 24 | -335.2% | 18.0% | ||
| Q2 24 | -267.6% | -16.4% | ||
| Q1 24 | -286.9% | — |
| Q4 25 | $1.52 | $-0.06 | ||
| Q3 25 | $-1.18 | $0.03 | ||
| Q2 25 | $-1.63 | $0.00 | ||
| Q1 25 | $-4.32 | $-0.05 | ||
| Q4 24 | $-4.24 | $0.10 | ||
| Q3 24 | $-4.01 | $0.03 | ||
| Q2 24 | $-3.00 | $-0.03 | ||
| Q1 24 | $-2.89 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.2M | $14.7M |
| Total DebtLower is stronger | $483.1M | — |
| Stockholders' EquityBook value | $-166.2M | $48.2M |
| Total Assets | $410.5M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.2M | $14.7M | ||
| Q3 25 | $6.2M | $13.6M | ||
| Q2 25 | $5.3M | $17.9M | ||
| Q1 25 | $18.0M | $19.5M | ||
| Q4 24 | $937.0K | $19.8M | ||
| Q3 24 | $317.0K | $27.4M | ||
| Q2 24 | $9.7M | $23.4M | ||
| Q1 24 | $8.2M | — |
| Q4 25 | $483.1M | — | ||
| Q3 25 | $484.9M | — | ||
| Q2 25 | $478.3M | — | ||
| Q1 25 | $480.0M | — | ||
| Q4 24 | $436.8M | — | ||
| Q3 24 | $398.4M | — | ||
| Q2 24 | $374.0M | — | ||
| Q1 24 | $329.8M | — |
| Q4 25 | $-166.2M | $48.2M | ||
| Q3 25 | $-158.1M | $52.9M | ||
| Q2 25 | $-132.7M | $49.9M | ||
| Q1 25 | $-134.5M | $45.2M | ||
| Q4 24 | $-100.5M | $43.2M | ||
| Q3 24 | $-65.6M | $32.4M | ||
| Q2 24 | $-32.8M | $28.6M | ||
| Q1 24 | $-9.4M | — |
| Q4 25 | $410.5M | $82.3M | ||
| Q3 25 | $417.8M | $82.3M | ||
| Q2 25 | $426.8M | $78.5M | ||
| Q1 25 | $447.2M | $73.9M | ||
| Q4 24 | $428.0M | $73.4M | ||
| Q3 24 | $430.8M | $61.6M | ||
| Q2 24 | $438.1M | $91.5M | ||
| Q1 24 | $413.4M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.1M | $2.0M |
| Free Cash FlowOCF − Capex | $-3.6M | $1.6M |
| FCF MarginFCF / Revenue | -29.1% | 17.8% |
| Capex IntensityCapex / Revenue | 3.9% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-42.9M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.1M | $2.0M | ||
| Q3 25 | $-8.9M | $-3.7M | ||
| Q2 25 | $-8.7M | $-5.2M | ||
| Q1 25 | $-9.6M | $-5.1M | ||
| Q4 24 | $1.2M | $4.0M | ||
| Q3 24 | $-17.2M | $4.1M | ||
| Q2 24 | $-4.0M | $-3.6M | ||
| Q1 24 | $-7.1M | — |
| Q4 25 | $-3.6M | $1.6M | ||
| Q3 25 | $-10.1M | $-4.2M | ||
| Q2 25 | $-14.6M | $-5.7M | ||
| Q1 25 | $-14.5M | $-5.4M | ||
| Q4 24 | $-8.6M | $3.6M | ||
| Q3 24 | $-30.0M | $4.0M | ||
| Q2 24 | $-28.8M | $-3.8M | ||
| Q1 24 | $-42.1M | — |
| Q4 25 | -29.1% | 17.8% | ||
| Q3 25 | -82.8% | -23.7% | ||
| Q2 25 | -121.0% | -36.2% | ||
| Q1 25 | -125.1% | -53.0% | ||
| Q4 24 | -85.3% | 19.6% | ||
| Q3 24 | -293.1% | 22.4% | ||
| Q2 24 | -305.4% | -28.1% | ||
| Q1 24 | -501.8% | — |
| Q4 25 | 3.9% | 4.4% | ||
| Q3 25 | 9.7% | 2.8% | ||
| Q2 25 | 48.9% | 2.8% | ||
| Q1 25 | 42.8% | 3.0% | ||
| Q4 24 | 97.6% | 2.3% | ||
| Q3 24 | 125.0% | 0.5% | ||
| Q2 24 | 263.0% | 1.3% | ||
| Q1 24 | 417.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LOCL
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
